Clinical trials: Oesophageal Cancer Metastatic
Esophageal Cancer, Gastric Cancer
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
The purpose of this study is to determine the safety and effectiveness of a combination of chemotherapy, capecitabine and oxaliplatin, plus the antibodies bevacizumab and trastuzumab.
- Trial name
- NCT01191697
- Testing
- bevacizumab, trastuzumab, oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced or Metastatic Solid Tumors, Microsatellite Instability Low
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab.
- Conditions
- Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High, Microsatellite Stable
- Trial name
- NCT05572684
- Testing
- NC410, pembrolizumab
- Where
- 17 sites in United States
- Volunteers
- 97 people
- Sponsor
- NextCure, Inc.
Esophageal Cancer
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
The purpose of this study is to test the safety and effectiveness of erlotinib and FOLFOX in patients with esophageal or gastro-esophageal cancer that cannot be removed by surgery.
- Trial name
- NCT00539617
- Testing
- Erlotinib, 5-fluorouracil, Leucovorin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of California, San Francisco
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer.
- Conditions
- Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- Spotlight (NCT03504397)
- Testing
- zolbetuximab, oxaliplatin, folinic acid
- Where
- 218 sites in United States, Australia and 18 more
- Volunteers
- 565 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastric Cancer
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with…
- Trial name
- HELOISE (NCT01450696)
- Testing
- Capecitabine, Cisplatin, Herceptin
- Where
- 117 sites in United States, Australia and 23 more
- Volunteers
- 296 people
- Sponsor
- Hoffmann-La Roche
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
This phase I/II trial studies the side effects and best dose of olaparib when given together with ramucirumab and how well they work in treating patients with gastric or gastroesophageal junction cancer that has spread to other…
- Conditions
- Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma
- Trial name
- NCT03008278
- Testing
- Olaparib, Ramucirumab
- Where
- 32 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy…
- Trial name
- NCT04921904
- Testing
- Abemaciclib, Ramucirumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Baylor Research Institute
Gastric Adenocarcinoma, Esophageal Adenocarcinoma
Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas
The initial intent of the study was to be a multi-center single-arm open-label Simon's two-stage Phase II clinical trial of first-line mFOLFOX6 + trastuzumab + avelumab in metastatic HER2-amplified gastric and esophageal…
- Conditions
- Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis, HER-2 Gene Amplification
- Trial name
- NCT03783936
- Testing
- Oxaliplatin, Leucovorin, 5 fluorouracil
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- Ashwin Somasundaram
Esophageal Carcinoma, Hypopharyngeal Carcinoma
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
This randomized pilot clinical trial studies the effects of taking doxepin hydrochloride as compared to placebo (inactive drug) in treating esophageal pain in patients with cancer located in the chest area receiving radiation…
- Conditions
- Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma
- Trial name
- NCT02062632
- Testing
- Doxepin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
This phase II trial studies how well pembrolizumab and palliative radiation therapy works in treating patients with esophagus, stomach, or gastroesophageal junction cancer that has spread to other parts of the body.
- Conditions
- Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach
- Trial name
- NCT02830594
- Testing
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Esophageal Cancer, Stomach Cancer
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
The purpose of this research study is to determine if the combination of docetaxel, cisplatin, irinotecan and bevacizumab will help shrink metastatic esophageal or gastric cancer and how the cancer responds to this combination.
- Trial name
- NCT00394433
- Testing
- Bevacizumab, Docetaxel, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Dana-Farber Cancer Institute
Gastric Adenocarcinoma, Barrett Esophagus
Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
This trial will be conducted to evaluate the efficacy, safety, and tolerability of sunitinib (sunitinib-malate) as a second-line palliative therapy in metastatic gastric cancer.
- Trial name
- NCT00411151
- Testing
- Sunitinib-Malate
- Where
- 12 sites in Germany
- Volunteers
- 52 people
- Sponsor
- Johannes Gutenberg University Mainz
Locally Advanced or Metastatic Malignant Solid Tumors
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
The primary purpose of this study is to determine the antitumor activity of enfortumab vedotin as measured by confirmed objective response rate (ORR) per RECIST v1.1.
- Trial name
- NCT04225117
- Testing
- enfortumab vedotin, pembrolizumab
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 329 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Esophageal Cancer
Combination Chemotherapy and Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00381706
- Testing
- cetuximab, ECF, IC
- Where
- 227 sites in United States
- Volunteers
- 245 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Stomach Neoplasms, Esophageal Neoplasms
Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
This study is being done to find out what effects a drug named/called bevacizumab has on patients and patients' tumors when given together with standard chemotherapy drugs.
- Trial name
- NCT00390416
- Testing
- Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
This phase 2 trial evaluates the benefit of epacadostat plus pembrolizumab in combination to treat patients with gastroesophageal junction or gastric cancer that has spread to other parts of the body and cannot be removed by…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma
- Trial name
- NCT03196232
- Testing
- Epacadostat, Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- George Albert Fisher
Esophageal Carcinoma
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the…
- Trial name
- NCT03099382
- Testing
- camrelizumab, Docetaxel, Irinotecan
- Where
- 2 sites in China
- Volunteers
- 457 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus
Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia
In this study, Erlotinib and 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (a regimen known also as FOLFOX-6) will be the chemotherapy study drugs.
- Conditions
- Unresectable Adenocarcinoma of the Esophagus, Metastatic Adenocarcinoma of the Esophagus, Unresectable Adenocarcinoma of Gastric Cardia, Metastatic Adenocarcinoma of Gastric Cardia
- Trial name
- NCT00591123
- Testing
- FOLFOX, 5-FU, Erlotinib
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Translational Oncology Research International
Esophageal Carcinoma, Esophagogastric Junction Carcinoma
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
In the China extension study, Chinese participants with advanced or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or Siewert type I adenocarcinoma of the esophagogastric junction (EGJ) that has progressed…
- Trial name
- NCT03933449
- Testing
- pembrolizumab, paclitaxel, docetaxel
- Where
- 23 sites in China
- Volunteers
- 123 people
- Sponsor
- Merck Sharp & Dohme LLC